Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
H. Fu, H. Fang, Jie Sun, H. Wang, A. Liu, J. Sun and Z. Wu
Pages 3271-3280 (10)
Since Bortezomib was approved by US FDA as the first drug to treat multiple myeloma, various boronic acid
compounds have been developed as enzyme inhibitors. This paper reviewed the progress of boronic acid-based inhibitors
against enzymes including proteasome, serine protease, HDACs and other enzymes in the past decade.
Boronic acid, bortezomib, enzyme inhibitor, HDACs, proteasome inhibitor, serine protease.
Institute of Materia Medica, Shandong Academy of Medical Sciences, 18877 Jingshi Rd., Ji’nan, Shandong 250062, China.